The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Shortened version of HER2 protein may drive treatment resistance in breast cancer, Mayo study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Mayo Clinic researchers have discovered why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account